Table 3.

Most frequently reported adverse events in the study population

Treatment/dose (no.)	Dizziness, no. (%)	Headache, no. (%)	Nausea, no. (%)	Vomiting, no. (%)
800 mg of (+)-mefloquine (8)	1 (12.5)	4 (50.0)	0 (0.0)	0 (0.0)
1,200 mg of (+)-mefloquine (4)	3 (75.0)	1 (25.0)	3 (75.0)	3 (75.0)
1,600 mg of (+)-mefloquine (7)	3 (42.9)	5 (71.4)	4 (57.1)	3 (42.9)
500 mg of racemic mefloquine (8)	2 (25.0)	2 (25.0)	1 (12.5)	0 (0.0)
750 mg of racemic mefloquine (4)	2 (50.0)	0 (0.0)	1 (25.0)	0 (0.0)
1,000 mg of racemic mefloquine (6)	4 (66.7)	1 (16.7)	1 (16.7)	1 (16.7)
Placebo (9)	1 (11.1)	2 (22.2)	3 (33.3)	1 (11.1)